Actively Recruiting
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Led by Alnylam Pharmaceuticals · Updated on 2026-05-14
40
Participants Needed
1
Research Sites
71 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
CONDITIONS
Official Title
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient with a confirmed diagnosis of Type 2 Diabetes Mellitus
- Body mass index (BMI) of 25 kg/m² or greater and less than 39.9 kg/m²
- Hemoglobin A1c (HbA1c) between 6.5% and less than 10.5%
- On a stable dose of metformin
You will not qualify if you...
- Any clinically significant disease, medical condition, or abnormal lab finding that could affect safety or study results
- Receiving treatments that interfere with glucose or insulin metabolism other than current T2DM treatment or birth control methods
- Other protocol-defined exclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Trial Site
Chula Vista, California, United States, 91911
Actively Recruiting
Research Team
A
Alnylam Clinical Trial Information Line
CONTACT
A
Alnylam Clinical Trial Information Line
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here